24 August 2018

Contents

Editorial

• 24 August 2018: vol 19 no 14: AIDS 2018 – next reports…

Conference reports

• 22nd International AIDS Conference (AIDS 2018) – second reports

• Namibia close to achieving 90-90-90 targets

• Dolutegravir monotherapy: still no longer recommended in either research or clinical practice

• Changing comorbidities in HIV positive people older than 60 at London clinic

• High acceptability of annual digital (finger) exam for early detection of anal cancer in gay men >35 years old

• High rates of anal HPV infection in gay men using PrEP in IPERGAY: the role of vaccination

• HCV incidence and reinfection in HIV negative gay men using PrEP in the Netherlands

• FDA-approved compounds that might selectively reverse HIV latency

• Lack of impact on viral reservoir with α4β7 monoclonal antibody vedolizumab: macaque results not matched in humans

• Janssen HIV vaccine: update from APPROACH and largescale efficacy study

• Viral load testing in Latin America and the Caribbean

• Access to viral load testing increased from 14% to 61% over two years in Côte d’Ivoire

• Resolving a diagnosis for people with persistently indeterminate HIV test results

• 10th International Workshop on HIV Paediatrics – second reports

• Dolutegravir dispersible tablets for infants and young children: early PK, safety and efficacy

Antiretrovirals

• Top-line phase 3 results released for cabotegravir/rilpivirine long-acting injections

• Interactions between oral anticoagulants and Genvoya, Stribild and cobicistat: FDA label updates

Other news

• More than ten people a day died from drug-related deaths in England and Wales last year:

On the web

• We learn, we think, we change: Martin Fisher Foundation and Stiggy launch campaign to end stigma

PDFs

• 24 August 2018: vol 19 no 14